JAK2V617F mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance

British Journal of Haematology

Volumn 131, Issue 2, 2005, Pages 208-213

  Wolanskyj, Alexandra P ^a   Lasho, Terra L ^a   Schwager, Susan M ^a   McClure, Rebecca F ^a   Wadleigh, Martha ^b   Lee, Stephanie J ^b   Gilliland, D Gary ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Essential thrombocythaemia; JAK2 mutation; Myeloproliferative disorders; Prognosis

Indexed keywords

JANUS KINASE 2; HEMOGLOBIN; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AGING; ALLELE; ARTICLE; BLOOD CELL; BONE MARROW CELL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HOMOZYGOSITY; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; THROMBOCYTHEMIA; THROMBOSIS; AGE; DISEASE COURSE; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POINT MUTATION; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOFIBROSIS; POINT MUTATION; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 27744606173     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05764.x     Document Type: Article

References (28)

1. Axelrad A.A. Eskinazi D. Correa P.N. Amato D. ( 2000) Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythaemia. Blood, 96, 3310 3321.
2. Barbui T. Barosi G. Grossi A. Gugliotta L. Liberato L.N. Marchetti M. Mazzucconi M.G. Rodeghiero F. Tura S. ( 2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 89, 215 232.
3. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. Vassiliou G.S. Bench A.J. Boyd E.M. Curtin N. Scott M.A. Erber W.N. Green A.R. ( 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
4. Elliott M.A. Tefferi A. ( 2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 128, 275 290.
5. Fialkow P.J. Faguet G.B. Jacobson R.J. Vaidya K. Murphy S. ( 1981) Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood, 58, 916 919.
6. Goerttler P.S. Steimle C. Marz E. Johansson P.L. Andreasson B. Griesshammer M. Gisslinger H. Heimpel H. Pahl H.L. ( 2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood First Edition Paper, prepublished online June 28, 2005; DOI 10.1182/blood-2005-04-1515.
7. Harrison C.N. ( 2005) Essential thrombocythaemia: challenges and evidence-based management. British Journal of Haematology, 130, 153 165.
8. Harrison C.N. Gale R.E. Pezella F. Mire-Sluis A. MacHin S.J. Linch D.C. ( 1999a) Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. British Journal of Haematology, 107, 139 147.
9. Harrison C.N. Gale R.E. Machin S.J. Linch D.C. ( 1999b) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood, 93, 417 424.
10. Jaffe E.S. Harris N.L. Stein H. Vardiman J.W. ( eds) ( 2001) WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. IARC press, Lyon.
11. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. Garcon L. Raslova H. Berger R. Bennaceur-Griscelli A. Villeval J.L. Constantinescu S.N. Casadevall N. Vainchenker W. ( 2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148.
12. Jelinek J. Oki Y. Gharibyan V. Bueso-Ramos C. Prchal J.T. Verstovsek S. Beran M. Estey E. Kantarjian H.M. Issa J.P. ( 2005) JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood First Edition Paper, prepublished online July 21, 2005; DOI 10.1182/blood-2005-05-1800.
13. Jones A.V. Kreil S. Zoi K. Waghorn K. Curtis C. Zhang L. Score J. Seear R. Chase A.J. Grand F.H. White H. Zoi C. Loukopoulos D. Terpos E. Vervessou E.C. Schultheis B. Emig M. Ernst T. Lengfelder E. Hehlman R. Hochhaus A. Oscier D. Silver R.T. Reiter A. Cross N.C.P. ( 2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood First Edition Paper, prepublished online May 26, 2005; DOI 10.1182/blood-2005-03-1320.
14. Juvonen E. Ikkala E. Oksanen K. Ruutu T. ( 1993) Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. British Journal of Haematology, 83, 192 197.
15. Koch C.A. Lasho T.L. Tefferi A. ( 2004) Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. British Journal of Haematology, 127, 34 39.
16. Kralovics R. Passamonti F. Buser A.S. Soon-Siong T. Tiedt R. Passweg J.R. Tichelli A. Cazzola M. Skoda R.C. ( 2005) A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
17. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. Boggon T.J. Wlodarska I. Clark J.J. Moore S. Adelsperger J. Koo S. Lee J.C. Gabriel S. Mercher T. D'Andrea A. Frohling S. Dohner K. Marynen P. Vandenberghe P. Mesa R.A. Tefferi A. Griffin J.D. Eck M.J. Sellers W.R. Meyerson M. Golub T.R. Lee S.J. Gilliland D.G. ( 2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387 397.
18. Messinezy M. Westwood N.B. El-Hemaidi I. Marsden J.T. Sherwood R.S. Pearson T.C. ( 2002) Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology, 117, 47 53.
19. Michiels J.J. Thiele J. ( 2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). International Journal of Hematology, 76, 133 145.
20. Passamonti F. Rumi E. Pungolino E. Malabarba L. Bertazzoni P. Valentini M. Orlandi E. Arcaini L. Brusamolino E. Pascutto C. Cazzola M. Morra E. Lazzarino M. ( 2004a) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 117, 755 761.
21. Passamonti F. Pietra D. Malabarba L. Rumi E. Della Porta M.G. Malcovati L. Bonfichi M. Pascutto C. Lazzarino M. Cazzola M. ( 2004b) Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 126, 650 656.
22. Reeder T.L. Bailey R.J. Dewald G.W. Tefferi A. ( 2003) Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood, 101, 1981 1983.
23. Steensma D.P. Dewald G.W. Lasho T.L. Powell H.L. McClure R.F. Levine R.L. Gilliland D.G. Tefferi A. ( 2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood First Edition Paper, prepublished online April 28, 2005; DOI 10.1182/blood-2005-03-1183.
24. Tefferi A. Fonseca R. Pereira D.L. Hoagland H.C. ( 2001) A long-term retrospective study of young women with essential thrombocythemia. Mayo Clinic Proceedings, 76, 22 28.
25. Tefferi A. Lasho T.L. Wolanskyj A.P. Mesa R.A. ( 2004a) Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood, 103, 3547 3548.
26. Tefferi A. Lasho T.L. Brockman S.R. Elliott M.A. Dispenzieri A. Pardanani A. ( 2004b) FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica, 89, 871 873.
27. V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology. in press Gilliland D.G. ( 2005b) Concomitant neutrophil JAK2 V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythemia. British Journal of Haematology. Online publication date, 6 September 2005, doi: 10.1111/j.1365-2141.2005.05743.x Tefferi A. ( 2000) Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. European Journal of Haematology, 65, 170 174.
28. Zhao R. Xing S. Li Z. Fu X. Li Q. Krantz S.B. Zhao Z.J. ( 2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry, 280, 22788 22792.